Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Boothbay Fund Management LLC

Boothbay Fund Management LLC lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 85,649 shares of the biotechnology company's stock after selling 63,776 shares during the quarter. Boothbay Fund Management LLC owned approximately 0.40% of Enanta Pharmaceuticals worth $492,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of ENTA. China Universal Asset Management Co. Ltd. purchased a new position in Enanta Pharmaceuticals during the 4th quarter worth $26,000. Tower Research Capital LLC TRC lifted its position in Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares during the period. Intech Investment Management LLC purchased a new stake in Enanta Pharmaceuticals in the 4th quarter valued at approximately $58,000. Wells Fargo & Company MN raised its stake in shares of Enanta Pharmaceuticals by 69.6% during the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock worth $91,000 after buying an additional 6,518 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $105,000. Institutional investors and hedge funds own 94.99% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ENTA shares. StockNews.com upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th. HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly bought 45,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Wednesday, February 12th. The shares were purchased at an average cost of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the transaction, the chief executive officer now owns 846,638 shares of the company's stock, valued at $4,817,370.22. This represents a 5.61 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 13.89% of the company's stock.

Enanta Pharmaceuticals Stock Performance

ENTA stock traded down $0.06 during trading on Tuesday, hitting $5.38. The stock had a trading volume of 49,118 shares, compared to its average volume of 285,697. The stock has a market cap of $114.77 million, a price-to-earnings ratio of -1.09 and a beta of 0.81. The company's 50 day moving average price is $5.86 and its two-hundred day moving average price is $7.01. Enanta Pharmaceuticals, Inc. has a 1-year low of $4.09 and a 1-year high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.